Kornitzer Capital Management Inc. KS Purchases 35,600 Shares of IQVIA Holdings Inc. $IQV

Kornitzer Capital Management Inc. KS grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 335.8% in the 1st quarter, HoldingsChannel.com reports. The fund owned 46,200 shares of the medical research company’s stock after buying an additional 35,600 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in IQVIA were worth $7,879,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA in the fourth quarter worth about $25,000. International Assets Investment Management LLC bought a new position in IQVIA during the 4th quarter valued at approximately $27,000. Gilpin Wealth Management LLC purchased a new stake in IQVIA in the 4th quarter worth approximately $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $28,000. Finally, Activest Wealth Management increased its stake in shares of IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after buying an additional 118 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the subject of a number of recent analyst reports. Evercore restated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Robert W. Baird lifted their price target on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Fourteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $224.82.

IQVIA Stock Down 0.4%

Shares of IQV traded down $0.84 during mid-day trading on Friday, reaching $208.13. The company had a trading volume of 747,394 shares, compared to its average volume of 1,464,238. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The company has a market capitalization of $34.74 billion, a price-to-earnings ratio of 25.79, a price-to-earnings-growth ratio of 1.79 and a beta of 1.20. The firm has a 50-day moving average price of $181.62 and a 200 day moving average price of $188.78. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the company earned $2.70 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.